Hyaluronic acid-targeted mixed micelles encapsulating hypericin for breast cancer photodynamic therapy

Recent advances in stimuli-responsive hyaluronic acid-based nanodelivery systems for cancer treatment: A review

Cancer is a worldwide public health problem that poses a serious threat to human health. Drug therapy, as the mainstay of cancer treatment, relies on carriers for the in vivo delivery of chemotherapeutic or nucleic acid-based drugs. Traditional drug delivery carriers have shortcomings, however, including a lack of targeting, uncontrollable release of drugs, and low stability, potentially leading to toxic side effects and reducing their antitumor efficacy. Advances in nanotechnology and biomedicine have furthered the development of stimuli-responsive nanodelivery systems, which can be used to realize the accumulation and on-demand release of drugs and reduce the required drug dosage and toxicity. Hyaluronic acid (HA), as a natural anionic polysaccharide with excellent biocompatibility, an easily modified structure, and the ability to target cancer cells, is a US Food and Drug Administration-approved biomaterial that is ideal for the construction of stimuli-responsive nanodelivery systems. Herein, we review HA-based stimuli-responsive nanodelivery systems including various HA-modified structures. We summarize the feasibility and effectiveness of these systems in cancer therapy according to their roles as endogenous- (pH, redox, enzyme, and hypoxia) or exogenous- (light, temperature, ultrasound, and magnetism) stimuli-responsive systems. We also discuss the problems and challenges in the development of HA-based stimuli-responsive nanodelivery systems and the perspectives for future development. This review highlights the great potential of HA-based stimuli-responsive nanodelivery systems for use in precision cancer treatment and controlled drug release.

Transforming Medicine with Nanobiotechnology: Nanocarriers and Their Biomedical Applications

Nanobiotechnology, at the intersection of nanotechnology and biology, represents a burgeoning field poised to revolutionize medicine through the use of advanced nanocarriers. These nanocarriers, endowed with distinctive physiobiological attributes, are instrumental in diverse therapeutic domains including drug delivery for microbial infections, cancer treatment, tissue engineering, immunotherapy, and gene therapy. Despite the transformative potential, several challenges hinder their efficacy, such as limited drug capacity, suboptimal targeting, and poor solubility. This review delves into the latest advancements in nanocarrier technologies, examining their properties, associated limitations, and the innovative solutions developed to address these issues. It highlights promising nanocarrier systems like nanocomposites, micelles, hydrogels, microneedles, and artificial cells that employ advanced conjugation techniques, sustained and stimulus-responsive release mechanisms, and enhanced solubility. By exploring these novel structures and their contributions to overcoming existing barriers, the article emphasizes the vital role of interdisciplinary research in advancing nanobiotechnology. This field offers unparalleled opportunities for precise and effective therapeutic delivery, underscoring its potential to reshape healthcare through personalized, targeted treatments and improved drug performance.

Nanoparticle-based materials in anticancer drug delivery: Current and future prospects

The past decade has witnessed a breakthrough in novel strategies to treat cancer. One of the most common cancer treatment modalities is chemotherapy which involves administering anti-cancer drugs to the body. However, these drugs can lead to undesirable side effects on healthy cells. To overcome this challenge and improve cancer cell targeting, many novel nanocarriers have been developed to deliver drugs directly to the cancerous cells and minimize effects on the healthy tissues. The majority of the research studies conclude that using drugs encapsulated in nanocarriers is a much safer and more effective alternative than delivering the drug alone in its free form. This review provides a summary of the types of nanocarriers mainly studied for cancer drug delivery, namely: liposomes, polymeric micelles, dendrimers, magnetic nanoparticles, mesoporous nanoparticles, gold nanoparticles, carbon nanotubes and quantum dots. In this review, the synthesis, applications, advantages, disadvantages, and previous studies of these nanomaterials are discussed in detail. Furthermore, the future opportunities and possible challenges of translating these materials into clinical applications are also reported.